Effects of growth hormone on circulating cytokine network, and left ventricular contractile performance and geometry in patients with idiopathic dilated cardiomyopathy

European Heart Journal

Volumn 24, Issue 24, 2003, Pages 2186-2196

  Adamopoulos, Stamatis ^a,b   Parissis, John T ^a   Paraskevaidis, Ioannis ^a   Karatzas, Dimitrios ^a   Livanis, Efthimios ^a   Georgiadis, Michael ^a   Karavolias, George ^a   Mitropoulos, Dimitrios ^a   Degiannis, Dimitrios ^a   Kremastinos, Dimitrios Th ^a  

^a ONASSIS CARDIAC SURGERY CENTER   (Greece)

^b FESC   (Greece)

Author keywords

Adhesion molecules; Cardiac remodelling; Chronic heart failure; Contractile performance; Cytokines; Dilated cardiomyopathy; Growth hormone; Inflammation

Indexed keywords

CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; GROWTH HORMONE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; TRANSFORMING GROWTH FACTOR BETA2; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSSOVER PROCEDURE; CYTOKINE PRODUCTION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; EXERCISE; FEMALE; GEOMETRY; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE CONTRACTILITY; HEART LEFT VENTRICLE PERFORMANCE; HEART LEFT VENTRICLE VOLUME; HEART MUSCLE OXYGEN CONSUMPTION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HORMONAL THERAPY; HORMONE ACTION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INFLAMMATION; MALE; PRIORITY JOURNAL; PROTEIN DETERMINATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANALYSIS OF VARIANCE; CARDIOMYOPATHY, DILATED; CYTOKINES; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; GROWTH HORMONE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL CONTRACTION; VENTRICULAR DYSFUNCTION, LEFT;

EID: 10744233124     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0195-668X(03)00480-9     Document Type: Article

References (43)

1. Mann DL. Mechanisms and models in heart failure: a combinatorial approach. Circulation 1999;100:999-1008.
2. Mann DL, Young JB. Basic mechanisms in congestive heart failure: recognizing the role of proinflammatory cytokines. Chest 1994;105:897-904.
3. Sasayama S, Matsumori A, Kihara Y. New insights into the pathophysiological role for cytokines in heart failure. Cardiovasc Res 1999;42:557-64.
4. Aukrust P, Ueland T, Lien E et al. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1999;83:376-82.
5. Deswal A, Mistra A, Bozkurt B. The role of anti-cytokine therapy in the failing heart. Heart Fail Rev 2001;6(2):143-51.
6. Yang R, Bunting S, Gillett N et al. Growth hormone improves cardiac performance in experimental heart failure. Circulation 1995;92:262-7.
7. Hongo M, Ryoke T, Schoenfeld J et al. Effects of growth hormone on cardiac dysfunction and gene expression in genetic murine dilated cardiomyopathy. Basic Res Cardiol 2000;95:431-41.
8. Fazio S, Sabatini D, Capaldo B et al. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med 1996;334:809-14.
9. Perrot A, Ranke MD, Dietz R et al. Growth hormone treatment in dilated cardiomyopathy. J Card Surg 2001;16:127-31.
10. Napoli R., Guardasole V, Matarazzo M et al. Growth hormone corrects vascular dysfunction in patients with chronic heart failure. J Am Coll Cardiol 2002;39:90-5.
11. Paraskevaidis IA, Adamopoulos S, Kremastinos DT. Dobutamine echocardiographic study in patients with nonischemic dilated cardiomyopathy and prognostically bordeline values of peak exercise oxygen consumption. J Am Coll Cardiol 2001;37:1685-91.
12. Riley M, Northidge DB, Henderson E et al. The use of an exponential protocol for bicycle and treadmill exercise testing in patients with chronic heart failure. Eur Heart J 1992;13:1363-7.
13. Gould KL, Lipscomb K, Hamilton GW et al. Relation of left ventricular shape, function and wall stress in man. Am J Cardiol 1974;34:627-34.
14. Paraskevaidis IA, Tsiapras DP, Adamopoulos S et al. Assessment of the functional status of heart failure in nonischemic dilated cardiomyopathy: an echo-dobutamine study. Cardiovasc Res 1999;43:58-66.
15. Borow KM, Lang RM, Neuman A et al. Physiologic mechanisms governing hemodynamic response to positive inotropic therapy in patients with dilated cardiomyopathy. Circulation 1988;77:625-37.
16. Devereux RB, Koren MJ, De Simone G et al. Methods for detection of left ventricular hypertrophy: application to hypertensive heart disease. Eur Heart J; (Suppl. D) 1993;14:8-15.
17. Hills M, Armitage P. The two-period cross-over clinical trials. Br J Clin Pharmacol 1979;8:7-20.
18. Adamopoulos S, Parissis J, Kremastinos D. A glossary of circulating cytokines in chronic heart failure. Eur J Heart Fail 2001;3(5):517-26.
19. Feldman AM, Combes A, Wagner D et al. The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol 2000;35:537-44.
20. Anker SD, Clark AL, Kemp M et al. Tumor necrosis factor-( and steroid metabolism in chronic heart failure: possible relation to muscle wasting. J Am Coll Cardiol 1997;30:997-2001.
21. Anker SD, Chua TP, Swan JW et al. Hormonal changes and catabolic/ anabolic imbalance in chronic heart failure: the importance of cardiac cachexia. Circulation 1997;96:526-34.
22. Katz SD, Rao R, Berman JW et al. Pathophysiological correlates of increased serum tumor necrosis factor in patients with congestive heart failure. Circulation 1994;90:12-6.
23. Pagel I, Langenickel T, Hohnel K et al. Cardiac and renal effects of growth hormone in volume overload-induced heart failure: role of NO. Hypertension 2002;39:57-62.
24. Ross J, Ryoke T. Effects of growth hormone and insulin-like growth factor-I in experimental heart failure. Growth Horm IGF Res; (Suppl. B) 1998;8:159-61.
25. Gu Y, Zou Y, Aikawa R et al. Growth hormone signalling and apoptosis in neonatal rat cardiomyocytes. Mol Cell Biochem 2001;223:35-46.
26. Genth-Zotz S, Zotz R, Geil S et al. Recombinant growth hormone therapy in patients with ischemic cardiomyopathy: effects on hemodynamics, left ventricular function and cardiopulmonary exercise capacity. Circulation 1999;99:18-21.
27. Parissis J, Adamopoulos S, Venetsanou K et al. Clinical and neurohormonal correlates of circulating granulocyte-macrophage colony-stimulating factor in severe heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 2000;86:707-10.
28. Sasayama S, Okada M, Matsumori A. Chemokines and cardiovascular diseases. Cardiovasc Res 2000;45:267-9.
29. Behr TM, Wang X, Aiyar N et al. Monocyte chemoattractant protein-1 is upregulated in rats with volume-overload congestive heart failure. Circulation 2000;102:1315-22.
30. Devaux B, Scholz D, Hirche A et al. Upregulation of cell adhesion molecules and the presence of low grade inflammation in human chronic heart failure. Eur Heart J 1997;18:470-9.
31. Taniguchi T, Koido Y, Aiboshi J et al. Change in the ratio of interleukin-6 to interleukin-10 predicts a poor outcome in patients with systemic inflammatory response syndrome. Crit Care Med 1999;27:1262-4.
32. Isgaard J, Bergh CH, Caidahl K et al. A placebo-controlled study of growth hormone in patients with congestive heart failure. Eur Heart J 1998;19:1704-11.
33. Cittadini A, Ines Comi L, Longobardi S et al. A preliminary randomized study of growth hormone administration in becker and Duchenne muscular dystrophies. Eur Heart J 2003;24:664-72.
34. Gullestad L, Aukrust P, Ueland T et al. Effect of high-versus low dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. J Am Coll Cardiol 1999;34:2061-7.
35. Ohtsuka T, Hamada M, Hiasa G et al. Effect of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy. J Am Coll Cardiol 2001;37:412-7.
36. Francis J, Weiss RM, Felder RB. Central mineralocorticoid receptor blockade decreases plasma tumor necrosis factor in rats with congestive heart failure (Abstract). Circulation; (Suppl. II) 2001;104:11-9.
37. Adamopoulos S, Parissis J, Kroupis C et al. Physical training reduces peripheral markers of inflammation in patients with chronic heart failure. Eur Heart J 2001;22:791-7.
38. Adamopoulos S, Parissis J, Karatzas D et al. Physical training modulates proinflammatory cytokines and soluble Fas-soluble Fas Ligand system in patients with chronic heart failure. J Am Coll Cardiol 2002;39:653-63.
39. Adamopoulos S, Parissis J, Georgiadis M et al. Growth hormone administration reduces circulating proinflammatory cytokines and soluble Fas/soluble FasLigand in patients with chronic heart failure secondary to idiopathic dilated cardiomyopathy. Am Heart J 2002;144:359-64.
40. Yamaoka M, Yamaguchi S, Okuyama M et al. Anti-inflammatory cytokine profile in human heart failure: behavior of interleukin-10 in association with tumor necrosis factor-alpha. Jpn Circ J 1999;6(12):951-6.
41. Volterrani M, Manelli F, Cicoira M et al. Role of growth hormone in chronic heart failure. Therapeutic implications. Drugs 2000;60:711-9.
42. Welch S, Plank D, Witt S et al. Cardiac-specific IGF-1 expression attenuates dilated cardiomyopathy in tropomodulin-overexpressing transgenic mice. Circ Res 2002;90:641-8.
43. Osterziel KJ, Bode-Boger SM, Strohm O et al. Role of nitric oxide in the vasodilator effect of recombinant human growth hormone in patients with dilated cardiomyopathy. Cardiovasc Res 2000;45:447-53.